BIOX to expand Synvisc marketing

Biomatrix Inc., after accepting some compromises to push its Synvisc osteoarthritis treatment into Canada in 1992, now has its sights on a series of major market milestones through the first part of 1994.
BIOX last week said Syntex Pharmaceuticals International Ltd. will market Synvisc in France, Great Britain, Scandinavia and Ireland. Synvisc, an injectable biopolymer derived from hyaluronan, is awaiting approval in the U.K. and Sweden.
On the heels of the Syntex deal, BIOX hopes